Acadia Pharma (ACAD) Tops Q3 EPS by 11c, Beats on Revenue; Offers FY26 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Acadia Pharma (ACAD) Tops Q3 EPS by 11c, Beats on Revenue; Offers FY26 Revenue Guidance

Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results

November 4, 2026 4:06 PM EST

- Third quarter GAAP total revenues of $342 million, up 22% year-over-year as compared to non-GAAP adjusted total revenues

- Third quarter DAYBUE® GAAP net sales of $140 million, up 39% year-over-year driven by strong uptake of DAYBUE STIX

- Third quarter NUPLAZID® GAAP net sales of $202 million, up 12% year-over-year on a non-GAAP adjusted basis

- Raises 2026 DAYBUE net sales guidance to $505$520 million; narrows NUPLAZID range and total revenue range

- Additional data from Phase 3-enabling RADIANT Phase 2 Study to be presented at the Clinical... More